RAPGEF4 and breast cancer: Thus, EPAC inhibition has been recognized as a promising therapeutic route for a wide spectrum of diseases, including pancreatic cancer [24], breast cancer [25], cardiac hypertrophy [26], vascular inflammation [27], Alzheimer’s disease [28], as well as infections, e.g., Coronavirus’ [29] and malaria [30].